This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-06 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
For services to the Post Office and to the community in Scunthorpe, Lincolnshire. Marion Constance Harrison. For services to the Schizophrenia Fellowship on Jersey. Maureen Hart, Personal Secretary, Vickers Defence Systems Ltd. For services to the Defence Industry. Patricia Mary Hart. For services to the community on Alderney. William Mark Hartley. For services to the community in Coventry. Dorothy Elizabeth Hawes, Vocal Department Consultant, Trinity College of Music, London. For services to Music Education. Judith Anne Hawkshaw. For services to Housing and the community in Suffolk. Shirley Caroline Amelia Hawley, lately Nursing Assistant, Pease Hill Residential Unit, Nottingham Healthcare Trust. For services to Health Care. Dinnie Margaret Hawthorne. For services to the community, particularly Elderly People in Bourne End, Buckinghamshire. Gordon Charles Hay, Gas Engineer. For humanitarian services to the former Yugoslavia. Arthur Rowland Hayter. For charitable services in Waterlooville, Hampshire. Desmond Heard, Gas Engineer. For humanitarian services to the former Yugoslavia. Albert Maurice Heath. For services to the Nevill Hall Hospital League of Friends, Abergavenny, Gwent. Alison Helen Constance Heath, Curator, the British Library. For services to Librananship and to Deaf People. Barbara Ceha Heath. For services to the community in Ringmer, East Sussex. Leslie Heath, Publican. For services to the community in East London. Patricia Ann Hedges, Education Advisor, Parcelforce. For services to the Freight Industry.
The Sindh government under PPP abolished child marriages by making the legal marriage age eighteen years in the province under the Sindh Child Marriages Restraint Act, 2013. He as a member of the opposition in the National Assembly has also advocated that the legal marriage age should be made eighteen years across the country. On 4 May 2019 he tweeted, "UAE marriage age is 18, Indonesia is 18, and Turkey is also 18. Are they not Muslim countries? In Sindh where marriage age is 18, we saw how law stopped an adult marrying a 10-year-old! Every 20 minutes a girl dies in Pakistan as a result of underage pregnancy.
The Jammu–Baramulla line of the Northern Railways is the only major railway line in Jammu and Kashmir. Its completion integrates the Kashmir Valley into India’s national rail grid and provides a direct rail link from other parts of India to the region. The line comprises Chenab Rail Bridge, the highest railway bridge in the world, and Anji Khad Bridge, the only cable-stayed railway bridge in India. The Udhampur-Srinagar-Baramulla Rail Link, a 272 km broad-gauge line that connects the Kashmir Valley to mainland India, achieved completion in December 2024 with the Reasi-Katra section (17 km), which features the Chenab Rail Bridge. The Banihal-Baramulla segment (118 km), among others, is electrified. The Jammu railway division, established in January 2025, oversees 742 km of operational tracks. It manages routes such as Pathankot-Jammu-Udhampur-Srinagar-Baramulla, Bhogpur Sirwal-Pathankot, Batala-Pathankot, and Pathankot-Joginder Nagar. The division oversees the operation of Vande Bharat Express trains between Jammu and Srinagar.
Thionyl chloride is an inorganic compound with the chemical formula SOCl2. It is a moderately volatile, colourless liquid with an unpleasant acrid odour. Thionyl chloride is primarily used as a chlorinating reagent, with approximately 45,000 tonnes (50,000 short tons) per year being produced during the early 1990s, but is occasionally also used as a solvent. It is toxic, reacts with water, and is also listed under the Chemical Weapons Convention as it may be used for the production of chemical weapons. Thionyl chloride is sometimes confused with sulfuryl chloride, SO2Cl2, but the properties of these compounds differ significantly. Sulfuryl chloride is a source of chlorine whereas thionyl chloride is a source of chloride ions.
Sources: en.wikipedia.org
In the first island chain, Taiwan is considered of critical strategic importance. It is located at the midpoint of the first chain and occupies a strategic position. The 2025 National Security Strategy noted Taiwan's strategic location dividing "Northeast and Southeast Asia into two distinct theatres". Submarine detection and tracking is less difficult on Taiwan's western coast where the waters are shallower than on Taiwan's eastern coast.
Glycerol is used in medical, pharmaceutical and personal care preparations, often as a means of improving smoothness, providing lubrication, and as a humectant. Ichthyosis and xerosis have been relieved by the topical use of glycerin. It is found in allergen immunotherapies, cough syrups, elixirs, expectorants, toothpastes, mouthwashes, skin care products, shaving cream, hair care products, soaps, and water-based personal lubricants. It is used to keep tablets and other solid dosage forms from falling apart. For human consumption, glycerol is classified by the FDA among the sugar alcohols as a caloric macronutrient. Glycerol is also used in blood banking to preserve red blood cells prior to freezing. Taken rectally, glycerol functions as a laxative by irritating the anal mucosa and inducing a hyperosmotic effect, expanding the colon by drawing water into it to induce peristalsis resulting in evacuation. It may be administered undiluted as a suppository, or as a small-volume (2–10 ml) enema. Alternatively, it may be administered in a dilute solution, such as 5%, as a high-volume enema. Taken orally (often mixed with fruit juice to reduce its sweet taste), glycerol can cause a rapid, temporary decrease in the internal pressure of the eye. This can be useful for the initial emergency treatment of severely elevated eye pressure. In 2017, researchers showed that the probiotic Limosilactobacillus reuteri bacteria can be supplemented with glycerol to enhance its production of antimicrobial substances in the human gut.
Colleagues recounted him saying that he didn't like working on minor injury wards or with old people and wanted to work in the emergency department because it was more 'exciting' for him. He said he "wasn't put on this earth to sit in an office." The hospital later found out that he had been secretly working as a nurse in other hospitals on occasions when he claimed to be off sick or attending a training course. His former partner said after his conviction that Norris had once hit him during an argument, bruising his head and once threw a bottle at him, which caused him to break up with Norris. He also said that, around the time of the murders, Norris had become engrossed by a storyline in Holby City, in which a serial killer nurse played by Rachel Leskovac killed patients with insulin before eventually being uncovered as a murderer. This same storyline is believed to have inspired another UK nurse, Benjamin Geen, to kill his patients. In the month in which he began killing patients with overdoses, Geen appeared in an edition of the Banbury Citizen which featured an interview with Leskovac. Norris's partner also revealed, after Norris's conviction, that Norris had experimented on his cat Casper before he began killing patients, injecting it with a lethal dose of insulin. The partner had reported him to the police but Norris claimed the cat had died from hitting its head on a wall.
=== Stress === Stress, to a physiologist, means any situation that threatens the continued stability of the body and its functions. Stress affects a wide variety of body systems: the two most consistently activated are the hypothalamic-pituitary-adrenal axis and the norepinephrine system, including both the sympathetic nervous system and the locus coeruleus-centered system in the brain. Stressors of many types evoke increases in noradrenergic activity, which mobilizes the brain and body to meet the threat. Chronic stress, if continued for a long time, can damage many parts of the body. A significant part of the damage is due to the effects of sustained norepinephrine release, because of norepinephrine's general function of directing resources away from maintenance, regeneration, and reproduction, and toward systems that are required for active movement. The consequences can include slowing of growth (in children), sleeplessness, loss of libido, gastrointestinal problems, impaired disease resistance, slower rates of injury healing, depression, and increased vulnerability to addiction.
==== Egypt ==== Egypt approved Viagra for sale in 2002, but soon afterwards allowed local companies to produce generic versions of the drug, citing the interests of poor people who would not be able to afford Pfizer's price.
Sources: en.wikipedia.org
== History of DHIS development == The original District Health Information Software (DHIS) was developed for three health districts in Cape Town as part of the Health Information Systems Programme (HISP), a collaborative research project between the University of Oslo and the University of the Western Cape that began in 1994.
=== Ratings and awards === In 2005 Hibiscus was one of three restaurants to be awarded three-stars by the Egon Ronay Restaurant Guide, along with The Waterside Inn and Restaurant Tom Aikens, and was named Ronay's Restaurant of the Year. The restaurant made its first entry in the World's 50 Best Restaurants in 2010, ranked in 49th place and one of three British restaurants in the list; the following year it moved up to 43rd. The Good Food Guide ranked Hibiscus as the eighth-best restaurant in the UK in its 2013 guide. The restaurant has been given five AA Rosettes by The Automobile Association.
==== MeSH D08.811.074 – dna repair enzymes ==== MeSH D08.811.074.124 – deoxyribodipyrimidine photo-lyase MeSH D08.811.074.249 – dna glycosylases MeSH D08.811.074.249.500 – DNA-formamidopyrimidine glycosylase MeSH D08.811.074.249.750 – thymine dna glycosylase MeSH D08.811.074.249.875 – uracil-dna glycosidase MeSH D08.811.074.500 – dna ligases MeSH D08.811.074.750 – DNA-(apurinic or apyrimidinic site) lyase MeSH D08.811.074.781 – muts dna mismatch-binding protein MeSH D08.811.074.812 – muts homolog 2 protein MeSH D08.811.074.875 – polynucleotide 5'-hydroxyl-kinase
== Discovery == Since the 1960s, seryl-tRNA synthetases have been described in various eukaryotic species, in both biochemical and structural analyses. It was not until 1997 that human SARS and its enzyme product were isolated and expressed in Escherichia coli by a team from The European Molecular Biology Laboratory in France.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.